Publications by authors named "Kim-Arthur Baffert"
Introduction: Quality of life (QoL) and patient satisfaction are major concerns in oncology.
Methods: The aim of this prospective observational study was to evaluate these parameters according to the mode of administration of anti-HER2 (subcutaneous [SC] versus intravenous [IV]), the place of administration (Home Hospitalization or HOD versus hospital) for patients supervised by an advanced practice nurse (APN).
Results: Between January 2022 and June 2023, 32 patients were included.
Article Synopsis
- A specific type of metastatic triple-negative breast cancer (mTNBC) shows increased sensitivity to platinum-based chemotherapy due to homologous recombination deficiency (HRD), prompting a study to explore genetic alterations and their impact on treatment response.
- In a study involving mTNBC patients, tumors were analyzed for mutations in 19 HRR genes, and patients were grouped based on their molecular status to evaluate responses to platinum therapy.
- Results indicated that mutations in specific HRR genes and promoter methylation were linked to better disease control, suggesting that broader genetic evaluations could help identify more patients who might benefit from platinum treatment.
Article Synopsis
- Identifying tumors with an active immune profile could help select advanced HNSCC and NSCLC patients for immunotherapy treatments.
- The study involved creating targeted gene expression profiles in different patient groups treated with PD-1/PD-L1 inhibitors, with comprehensive clinical information available for analysis.
- Additional datasets were generated from paired HNSCC biopsies and surgical specimens, providing insights into biomarker stability during diagnosis and recurrence.
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
Eur J Cancer
October 2022
Introduction: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our objective was to develop a reliable and stable scoring system to identify those immunologically active tumours.
Methods: Using gene expression profiles of 421 HNSCC, we developed a score to identify immunologically active tumours.
Article Synopsis
- * A study involving 120 patients explored the potential neuroprotective effects of renin-angiotensin system (RAS) inhibitors during chemotherapy, revealing that those on RAS inhibitors had lower severity of sensory neuropathy compared to those not on the inhibitor.
- * The study was observational, and while RAS inhibitors showed promise, further randomized controlled trials are needed to validate their effectiveness in preventing CIPN during platinum-based chemotherapy regimens.
Background: The COVID-19 pandemic has changed the organisation of medical care.
Patients And Methods: This is the first prospective observational study on patient-reported outcomes, quality of life (HRQOL) and satisfaction in patients with cancer with their care management in a day hospital during the period of May-June 2020. The Generalised Anxiety Disorder Screener and 12-Item Short-Form Health Survey were used.